Scientists with the National Institutes of Health announced on Sunday that a two-year-old child infected with HIV at birth had no signs of active virus despite being off anti-retroviral medication for nearly a year.
The baby, born in rural Mississippi, was treated aggressively with antiretroviral drugs starting around 30 hours after birth, something that is not usually done.
Typically a newborn with an infected mother would be given one or two drugs as a prophylactic measure. But Dr. Gay said that based on her experience, she almost immediately used a three-drug regimen aimed at treatment, not prophylaxis, not even waiting for the test results confirming infection.
The toddler is the second person to have been “functionally cured,” meaning that the child may be able to safely remain off of anti-HIV drugs even though trace amounts of the virus can be detected in her blood. The first person was the “Berlin Patient,” a man infected with HIV who received a stem-cell transplant to treat another disease (see “Bone Marrow Transplant Appears to Halt HIV”). The risky transplant procedure replaced his immune cells with immune cells from a donor who carried a genetic mutation that prevents HIV infection.
Like the Berlin Patient, the Mississippi toddler is a special cases and it may be that there is something unique about the still-developing immune systems of infants that enabled the potential cure. Researchers continue to pursue treatments such as genetically modifying immune stem cells for a more broadly applicable cure (see “Can AIDS Be Cured?”).
Still, as reported by the Los Angeles Times, the discovery offers hope for other infected infants:
If researchers demonstrate that the same treatment can work in other children, it could drastically alter the lives of the estimated 1,000 babies born with HIV every day, most of them in Africa, doctors said.
Attempting to replicate the results in other HIV-positive infants is “our next step,” said Dr. Deborah Persaud, a virologist at Johns Hopkins Children’s Center who described the Mississippi patient at the Conference on Retroviruses and Opportunistic Infections.
The big new idea for making self-driving cars that can go anywhere
The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.
Inside Charm Industrial’s big bet on corn stalks for carbon removal
The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.